• Harnessing three decades of understanding the underlying technology, we present a completely new continuous flow approach to RNA manufacturing. Our primary focus is on eliminating dsRNA impurities from the outset, to enable RNA therapies stuck in the pipeline.

    High purity

    By eliminating dsRNA production up front, we eliminate the need for costly (and inefficient) post-synthesis purification.

    Lower costs

    Continuous flow, with long manufacturing runs, plus increased yields of RNA per DNA.


    Fluidics system scale up to produce high volume therapeutic or down to personalized therapies.

Serving a wide and growing range of RNA products